With the mRNA market projected to have reached $63.28 billion by 2025, the global demand for mRNA vaccines and therapeutics is at an all-time high. Now more than ever, robust process development and manufacturing are essential to ensure patients have access to life-saving treatments. While the industry is making strides in continuous processing, advanced analytics, improved scalability, and innovative formulations, significant challenges remain, including controlling impurities, long manufacturing timelines, and navigating complex regulatory pathways for timely approvals.

The 3rd mRNA Process Development & Manufacturing Summit 2025 returned as Europe’s premier industry-focused forum, dedicated to optimising process development for mRNA therapeutics and vaccines. This event addressed end-to-end process optimisation, regulatory compliance to streamline approvals, while also advancing scalable and cost-efficient manufacturing solutions, to support drug developers in delivering safer and more effective mRNA drugs to patients faster.

The summit brought together leading experts from CEPI, Merck, CureVac, BioNTech, Altamira, Genevation, and more, showcasing cutting-edge advancements in end-to-end process development and manufacturing to support the production of high-quality, cost-effective mRNA therapeutics at scale.